• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

CorriXR Therapeutics

  • November 2, 2022
  • New Biotech Startups

CorriXR Therapeutics is an oncology-focused biotherapeutics developing a novel gene editing platform technology.

CorriXR has developed an innovative CRISPR/Cas molecule that disables the genome of a tumor cell but not the genome of a healthy cell thereby conferring target selectivity. It is uniquely directed towards knocking out genetic pathways to allow for a broad-based combinatorial therapeutic regimen for the treatment of solid tumors.

The company’s initial genetic pathway target is the NRF2 gene. The Nrf2 protein is a global transcriptional regulator that functions to activate genes in response to cellular stress and is implicated in progression of solid tumors. CorriXR’s objective is to use CRISPR-directed gene editing to disable NRF2 gene functions specifically in cancer cells. The company says preclinical data in both cell and animal models confirms that the NRF2 gene is a viable target for a gene editing therapeutic for solid tumors.

CorriXR Therapeutics is the inaugural biotech spin-out of ChristianaCare, a large healthcare system, and the Gene Editing Institute (GEI), which has been embedded in ChristianaCare’s Helen F. Graham Cancer Center & Research Institute since 2015.


Subscribe for alerts on new companies featured on Startups.Bio


September 21, 2023Function Oncology
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond measuring gene sequence to measuring …
July 17, 2023Mallia Therapeutics
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an immune modulator by Mallia co-founder …
April 21, 2023T-Therapeutics
T-Therapeutics is on a mission to unlock the power of T cells to treat chronic and infectious diseases. Founded in 2022, the company is based on technology from Professor Allan …
March 26, 2023Empyrean Neuroscience
Empyrean Neuroscience has developed a platform for genetically engineering small molecule therapeutics from fungi and plants to treat neuropsychiatric and neurologic disorders. Through precision targeting and engineering of the fungal …

View all recently featured startups


Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.